Table 2 Reasons for trastuzumab emtansine (T-DM1) discontinuation by age group.
Reason for discontinuation | ≤50 years | >50 years |
|---|---|---|
n | 93 | 191 |
Discontinuation for any reason | 8 (9) | 44 (23) |
Patient withdrew consent (n, %) | – | 4 (2) |
Unacceptable toxicity | 7 (8) | 35 (18) |
Physician decision | 4 | 18 |
Protocol-mandated | 3 | 17 |
Other | 1 (1) | 5 (3) |
Cumulative discontinuation through 1 year (n, %) | ||
0–3 months | 2 (2) | 7 (4) |
3–6 months | 3 (3) | 16 (8) |
6–9 months | 4 (4) | 32 (17) |
9–12 months | 8 (9) | 44 (23) |
Reasons for discontinuation due to toxicity (n, %)a | ||
Liver enzyme elevation/bilirubin elevation | 2 (29) | 10 (29) |
Neuropathy | 1 (14) | 6 (17) |
Platelet count decreased | 1 (14) | 6 (17) |
Bleeding | – | 2 (6) |
Cardiotoxicity | – | 2 (6) |
Cough/dyspnea | 2 (29) | – |
Nausea/vomiting | – | 3 (9) |
Anemia | 1 (14) | – |
Eye disorders - Other, specify | – | 1 (3) |
Fatigue | – | 1 (3) |
Headache | – | 1 (3) |
Myalgia | – | 1 (3) |
Pneumonitis | – | 1 (3) |
Telangiectasia | – | 1 (3) |
